Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Asia, Europe, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplant surgery; and ultrasound imaging probes for intraoperative use. It also provides QuickFit TTFM probes, which are designed to hold the vessel and ensure precise measurements on various types of vessel grafts; Vascular TTFM probes for locking slide mechanism designed to secure the vessel while minimizing the manipulation; ultrasound imaging probes; and Doppler probes that are used to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, the company distributes and sells third party medical equipment. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.…
MEDI: Rapporteringspliktig handel i Medistim ASA
Medistim (OSL: MEDI) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 159 employees.
The shares were at 319.00 NOK on 20 November 2026, up 33.3% over 52 weeks. Its 52-week range is 186.50 NOK to 330.00 NOK: the price is 3.3% below the high and 71.0% above the low.
At a market capitalisation of 5.83B NOK, it trades at 32.7 times trailing earnings and 27.1 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a premium of 28% for MEDI. It pays a dividend yielding 3.31% (it pays out 82% of its earnings), against a median of 2.35% among the dividend payers in that peer group.
Medistim reports return on equity of 34.0%, an operating margin of 28.6% and revenue up 25.9% year over year.
It holds more cash than debt, a net cash position of 149.39M NOK. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 2 analysts cover the stock; their mean price target of 365.00 NOK is 14.4% above the current price. The next earnings report is expected on 26 February 2027.